# US 2024/0254203 A1 · Antibody-based antivirus compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254203 A1
- Document ID: US20240254203A1
- Status: Published application
- Kind: A1
- Application number: 18/560,621
- Filed: 2022-05-19
- Published: 2024-08-01
- Earliest claimed: 2021-05-20
- Assignees: Achelois Biopharma, Inc.
- Applicants: Achelois BioPharma, Inc.
- Inventors: Michael CHEN; Chang-Zheng CHEN; Yiling LUO; Hua ZHOU
- Web page: https://patentgrep.com/patent/US20240254203A1

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07K 16/102: Coronaviridae (F)
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2039/6075: {Viral proteins}
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/73: containing coiled-coiled motif (leucine zippers)
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C12N 2740/15023: Virus like particles [VLP]
- C12N 2740/16023: Virus like particles [VLP]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18422: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus, wherein the fusion protein is expressed at a valency of at least about 10 copies on a surface of the antivirus, and wherein the antibody neutralizes the virus when expressed within the fusion protein on the surface of the antivirus but does not neutralize the virus when expressed as an isolated antibody. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-COV-2).

## Claims

### Claim 1

An antivirus comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus wherein the fusion protein is expressed at a valency of at least about 10 copies on a surface of the antivirus, wherein the antibody neutralizes the virus when expressed within the fusion protein on the surface of the antivirus, but does not neutralize the virus when expressed as an isolated antibody.

### Claim 2 (depends on 1)

The antivirus of claim 1, wherein the fusion protein further comprises an oligomerization domain.

### Claim 3 (depends on 2)

The antivirus of claim 2, wherein the oligomerization domain is a dimerization domain, a trimerization domain, or a tetramerization domain.

### Claim 4 (depends on 3)

The antivirus of claim 3, wherein the dimerization domain comprises a leucine zipper dimerization domain.

### Claim 5 (depends on 3)

The antivirus of claim 3, wherein the trimerization domain comprises a post-fusion oligomerization domain of viral surface protein.

### Claim 6 (depends on 3)

The antivirus of claim 3, wherein the trimerization domain comprises a D4 post-fusion trimerization domain of VSV-G protein.

### Claim 7 (depends on 3)

The antivirus of claim 3, wherein the trimerization domain comprises a Dengue E protein post-fusion trimerization domain.

### Claim 8 (depends on 3)

The antivirus of claim 3, wherein the trimerization domain comprises a foldon trimerization domain.

### Claim 9 (depends on 3)

The antivirus of claim 3, wherein the tetramerization domain comprises an influenza neuraminidase stem domain.

### Claim 10 (depends on 2)

The antivirus of claim 2, wherein the oligomerization domain comprises an amino acid sequence that is at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 11 (depends on 2)

The antivirus of claim 2, wherein when the fusion protein is expressed on the surface of the antivirus, the oligomerization domain is outside of the antivirus.

### Claim 12 (depends on 2)

The antivirus of claim 2, wherein when the fusion protein is expressed on the surface of the antivirus, the oligomerization domain is outside of the antivirus and adjacent to a signal peptide.

### Claim 13 (depends on 2)

The antivirus of claim 2, wherein when the fusion protein is expressed on the surface of the antivirus, the oligomerization domain is inside of the antivirus.

### Claim 14 (depends on 2)

The antivirus of claim 2, wherein when the fusion protein is expressed on the surface of the antivirus, the oligomerization domain is inside of the antivirus and adjacent to the transmembrane polypeptide.

### Claim 15 (depends on 1)

The antivirus of claim 1, wherein the fusion protein comprises a signal peptide.

### Claim 16 (depends on 1)

The antivirus of claim 1, wherein domains of the fusion protein are arranged from the N-terminus to the C-terminus in the following orders:
(a) signal peptide, antibody which binds to a surface protein of a virus, oligomerization domain, transmembrane polypeptide, and cytosolic domain;
(b) signal peptide, antibody which binds to a surface protein of a virus, transmembrane polypeptide, oligomerization domain, and cytosolic domain; or
(c) signal peptide, oligomerization domain, antibody which binds to a surface protein of a virus, transmembrane polypeptide, and cytosolic domain.

### Claim 17 (depends on 1)

The antivirus of claim 1, wherein the antibody comprises a single chain variable fragment (scFv), a single domain antibody, an Fv, a VH domain, a VL domain, a Fab fragment, a monoclonal antibody, F(ab′), F(ab′)2, single chain antibodies, diabodies, or a scFv-Fc.

### Claim 18 (depends on 1)

The antivirus of claim 1, wherein the antibody binds specifically to the surface protein of the virus.

### Claim 19 (depends on 1)

The antivirus of claim 1, wherein the antibody is a multispecific antibody.

### Claim 20 (depends on 19)

The antivirus of claim 19, wherein the multispecific antibody binds specifically to more than one epitope on the surface protein of the virus.

### Claim 21 (depends on 19)

The antivirus of claim 19, wherein the multispecific antibody comprises a tandem scFv format.

### Claim 22 (depends on 1)

The antivirus of claim 1, wherein the virus comprises SARS COV-1, SARS COV-2, influenza, or MERS CoV virus.

### Claim 23 (depends on 1)

The antivirus of claim 1, wherein the antibody comprises an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5.

### Claim 24 (depends on 1)

The antivirus of claim 1, wherein the antibody comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82.

### Claim 25 (depends on 1)

The antivirus of claim 1, wherein the transmembrane polypeptide anchors the fusion protein to a bilayer of the antivirus.

### Claim 26 (depends on 1)

The antivirus of claim 1, wherein the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA).

### Claim 27 (depends on 1)

The antivirus of claim 1, wherein the transmembrane polypeptide comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs.: 44-52.

### Claim 28 (depends on 1)

The antivirus of claim 1, wherein the transmembrane polypeptide comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to that set forth in SEQ ID NO: 29.

### Claim 29 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of about 10 copies on a surface of the antivirus.

### Claim 30 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of about 10 to 15 copies on a surface of the antivirus.

### Claim 31 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 25 copies on a surface of the antivirus.

### Claim 32 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 50 copies on a surface of the antivirus.

### Claim 33 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 100 copies on a surface of the antivirus.

### Claim 34 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 200 copies on a surface of the antivirus.

### Claim 35 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 400 copies on a surface of the antivirus.

### Claim 36 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 600 copies on a surface of the antivirus.

### Claim 37 (depends on 1)

The antivirus of claim 1, wherein the fusion protein is expressed at a valency of at least about 1000 copies on a surface of the antivirus.

### Claim 38 (depends on 1)

The antivirus of claim 1, wherein the antivirus is an enveloped particle.

### Claim 39 (depends on 1)

The antivirus of claim 1, wherein the antivirus does not comprise viral genetic material.

### Claim 40 (depends on 1)

The antivirus of claim 1, wherein the antivirus comprises a lipid bilayer.

### Claim 41 (depends on 1)

The antivirus of claim 1, wherein the antivirus is a virus.

### Claim 42 (depends on 1)

The antivirus of claim 1, wherein the antivirus is a replication incompetent virus.

### Claim 43 (depends on 1)

The antivirus of claim 1, wherein the antivirus is a replication competent virus.

### Claim 44 (depends on 1)

The antivirus of claim 1, wherein the antivirus is a viral-like particle.

### Claim 45 (depends on 1)

The antivirus of claim 1, wherein the fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 59-70, 72, 74, and 78.

### Claim 46 (depends on 1)

The antivirus of claim 1, wherein the antivirus further comprises a second fusion protein that comprises transmembrane polypeptide and a second antibody which binds to a surface protein of the virus, wherein the second antibody comprises a CDR sequence that has less than 100% sequence identity to an equivalent CDR sequence of the antibody.

### Claim 47 (depends on 46)

The antivirus of claim 46, wherein the fusion protein and the second fusion protein comprise the same transmembrane polypeptide.

### Claim 48 (depends on 46)

The antivirus of claim 46, wherein the fusion protein and the second fusion protein comprise different transmembrane polypeptides.

### Claim 49 (depends on 46)

The antivirus of claim 46, wherein the second antibody binds to the same surface protein as the antibody.

### Claim 50 (depends on 46)

The antivirus of claim 46, wherein the second antibody binds to a different surface protein as the antibody.

### Claim 51 (depends on 46)

The antivirus of claim 46, wherein the second antibody is a single chain variable fragment (scFv), a tandem scFv, a single domain antibody, an Fv, a VH domain, a VL domain, a Fab fragment, a monoclonal antibody, F(ab′), F(ab′)2, single chain antibodies, diabodies, or a scFv-Fc.

### Claim 52 (depends on 46)

The antivirus of claim 46, wherein the second antibody binds specifically to the surface protein of the virus.

### Claim 53 (depends on 46)

The antivirus of claim 46, wherein the second antibody is a multispecific antibody.

### Claim 54 (depends on 53)

The antivirus of claim 53, wherein the second multispecific antibody binds specifically to more than one epitope on the surface protein of the virus.

### Claim 55 (depends on 46)

The antivirus of claim 46, wherein the second antibody comprises an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15 and BG10-19.

### Claim 56 (depends on 46)

The antivirus of claim 46, wherein the second antibody comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28, and 81-86.

### Claim 57 (depends on 46)

The antivirus of claim 46, wherein the second antibody neutralizes the virus when expressed within the fusion protein but does not neutralize the virus when expressed as an isolated antibody.

### Claim 58 (depends on 46)

The antivirus of claim 46, wherein the second antibody neutralizes the virus when expressed within the fusion protein and neutralizes the virus when expressed as an isolated antibody.

### Claim 59 (depends on 46)

The antivirus of claim 46, wherein the second fusion protein further comprises an oligomerization domain.

### Claim 60 (depends on 59)

The antivirus of claim 59, wherein the oligomerization domain is a dimerization domain or a trimerization domain.

### Claim 61 (depends on 59)

The antivirus of claim 59, wherein the oligomerization domain comprises the D4 trimerization domain of VSV-G protein.

### Claim 62 (depends on 11)

The antivirus of claim 11, wherein the antibody comprises a single chain variable fragment (scFv) and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, and BG4-5.

### Claim 63 (depends on 46)

The antivirus of claim 46, wherein the second fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 53-72, 74-76, or 78.

### Claim 64 (depends on 1)

The antivirus of claim 1, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5; and
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA).

### Claim 65 (depends on 1)

The antivirus of claim 1, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5;
(b) the transmembrane polypeptide comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52.

### Claim 66 (depends on 1)

The antivirus of claim 1, wherein:
(a) the antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82; and
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA).

### Claim 67 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5; and
(b) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 68 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a single chain variable fragment (scFv) and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5; and
(b) the oligomerization domain comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 69 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82; and
(b) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 70 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5; and
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 71 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5;
(b) the transmembrane polypeptide comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 72 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5;
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 73 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5;
(b) the transmembrane polypeptide comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 74 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82;
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 75 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82;
(b) the transmembrane polypeptide comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 76 (depends on 2)

The antivirus of claim 2, wherein:
(a) the antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 6-14, 20-28 and 81-82;
(b) the transmembrane polypeptide comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 77 (depends on 46)

The antivirus of claim 46, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19; and
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA).

### Claim 78 (depends on 46)

The antivirus of claim 46, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19; and
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52.

### Claim 79 (depends on 46)

The antivirus of claim 46, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28; and
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA).

### Claim 80 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19; and
(b) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 81 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a single chain variable fragment (scFv) and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19; and
(b) the oligomerization domain of the second fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 82 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28; and
(b) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 83 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19; and
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, or an influenza neuraminidase stem tetramerization domain.

### Claim 84 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 85 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain of the second fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 86 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain of the second fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 87 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28 and 81-86;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 88 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28 and 81-86;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain comprising an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to one of SEQ ID NOs.: 44-52; and
(c) the oligomerization domain of the second fusion protein comprises a leucine zipper dimerization domain, a D4 trimerization domain of VSV-G protein, a Dengue E protein post-fusion trimerization domain, a foldon trimerization domain, an influenza neuraminidase stem tetramerization domain.

### Claim 89 (depends on 59)

The antivirus of claim 59, wherein:
(a) the second antibody comprises a scFv and an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 1-28 and 81-86;
(b) the transmembrane polypeptide of the second fusion protein comprises a transmembrane domain of a Vesicular Stomatitis virus glycoprotein (VSV-G), influenza Hemagglutinin (HA), HIV surface glycoprotein GP120 or GP41, measles virus surface glycoprotein hamagglutinin (H) protein, or influenza Neuraminidase (NA); and
(c) the oligomerization domain of the second fusion protein comprises an amino acid sequence at least about 80%, 85%, 90%, 95%, or 99% identical to any one of SEQ ID NOs: 30-43.

### Claim 90 (depends on 19)

The antivirus of claim 19, wherein the antibody is multispecific antibody that comprises a tandem scFv format comprising an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5 and an amino acid sequence from at least one complementarity determining region of 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018 and BG4-5 and the fusion protein oligomerization domain comprises the D4 trimerization domain of VSV-G protein.

### Claim 91 (depends on 53)

The antivirus of claim 53, wherein the second antibody is multispecific antibody that comprises a tandem scFv format comprising an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19 and an amino acid sequence from at least one complementarity determining region of 80R, H4, 7D10, 1E01, FI6, 0304-4A10, 2M-14E5, 9A1, COV2-2021, COV2-2026, COV2-2146, 2M-10B11, C021, C018, BG4-5, BG7-15, and BG10-19 and the second fusion protein oligomerization domain comprises the D4 trimerization domain of VSV-G protein.

### Claim 92

A composition comprising an antibody-based antivirus wherein the antibody-based antivirus comprises an enveloped particle that displays at least about 10 copies of an antibody on a surface of the antivirus, wherein the antibody binds to at least one surface protein of a virus, wherein one of the at least one surface protein of the virus comprises an oligomerized format, wherein the antibody neutralizes the virus when expressed on the surface of the antivirus, but does not neutralize the virus when expressed as an isolated antibody.

### Claim 93

A composition comprising an antibody-based antivirus wherein the antibody-based antivirus comprises an enveloped particle that displays at least about 10 copies of an antibody on a surface of the antivirus, wherein the antibody comprises an oligomerized format and binds to at least one surface protein of a virus, wherein one of the at least one surface protein of the virus comprises an oligomerized format, wherein the antibody neutralizes the virus when expressed as an isolated antibody.
